Effects of long-term pioglitazone treatment on peripheral and central markers of aging

PLoS ONE

Volumn 5, Issue 4, 2010, Pages

  Blalock, Eric M ^a   Phelps, Jeremiah T ^a   Pancani, Tristano ^a   Searcy, James L ^a   Anderson, Katie L ^a   Gant, John C ^a   Popovic, Jelena ^a   Avdiushko, Margarita G ^a   Cohen, Don A ^a   Chen, Kuey Chu ^a   Porter, Nada M ^a   Thibault, Olivier ^a  

^a UNIVERSITY OF KENTUCKY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INSULIN RECEPTOR; INTERLEUKIN 1BETA; INTERLEUKIN 6; PIOGLITAZONE; TUMOR NECROSIS FACTOR ALPHA; 2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIDIABETIC AGENT; BIOLOGICAL MARKER;

AFTERHYPERPOLARIZATION; AGING; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COGNITIVE DEFECT; CONTROLLED STUDY; EXCITATORY POSTSYNAPTIC POTENTIAL; HIPPOCAMPUS; INFLAMMATION; INSULIN BLOOD LEVEL; LEARNING; LONG TERM EXPOSURE; LONG TERM POTENTIATION; MALE; MEMORY; MENTAL PERFORMANCE; MICROARRAY ANALYSIS; NERVE CELL PLASTICITY; NONHUMAN; RAT; SPATIAL MEMORY; ALZHEIMER DISEASE; ANIMAL; BLOOD; BRAIN; DRUG EFFECT; LIVER; PHYSIOLOGY;

AGING; ALZHEIMER DISEASE; ANIMALS; BIOLOGICAL MARKERS; BRAIN; HIPPOCAMPUS; HYPOGLYCEMIC AGENTS; INFLAMMATION; LEARNING; LIVER; LONG-TERM POTENTIATION; MALE; MEMORY; RATS; THIAZOLIDINEDIONES;

EID: 77956402617     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0010405     Document Type: Article

References (121)

1. Gradman TJ, Laws A, Thompson LW, Reaven GM (1993) Verbal learning and/or memory improves with glycemic control in older subjects with non-insulin-dependent diabetes mellitus. J Am Geriatr Soc 41: 1305-1312.
2. Awad N, Gagnon M, Messier C (2004) The relationship between impaired glucose tolerance, type 2 diabetes, and cognitive function. J Clin Exp Neuropsychol 26: 1044-1080.
3. Gregg EW, Yaffe K, Cauley JA, Rolka DB, Blackwell TL, et al. (2000) Is diabetes associated with cognitive impairment and cognitive decline among older women? Study of Osteoporotic Fractures Research Group. Arch Intern Med 160: 174-180.
4. Messier C (2005) Impact of impaired glucose tolerance and type 2 diabetes on cognitive aging. Neurobiol Aging 26 Suppl 1: 26-30.
5. Reagan LP (2002) Glucose, stress, and hippocampal neuronal vulnerability. Int Rev Neurobiol 51: 289-324.
6. Ryan CM, Geckle M (2000) Why is learning and memory dysfunction in Type 2 diabetes limited to older adults? Diabetes Metab Res Rev 16: 308-315.
7. Zhao WQ, Alkon DL (2001) Role of insulin and insulin receptor in learning and memory. Mol Cell Endocrinol 177: 125-134.
8. Barrientos RM, Frank MG, Hein AM, Higgins EA, Watkins LR, et al. (2009) Time course of hippocampal IL-1 beta and memory consolidation impairments in aging rats following peripheral infection. Brain Behav Immun 23: 46-54.
9. Fishel MA, Watson GS, Montine TJ, Wang Q, Green PS, et al. (2005) Hyperinsulinemia provokes synchronous increases in central inflammation and beta-amyloid in normal adults. Arch Neurol 62: 1539-1544.
10. Godbout JP, Chen J, Abraham J, Richwine AF, Berg BM, et al. (2005) Exaggerated neuroinflammation and sickness behavior in aged mice following activation of the peripheral innate immune system. FASEB J 19: 1329-1331.
11. Prolla TA (2002) DNA microarray analysis of the aging brain. Chem Senses 27: 299-306.
12. Rosenzweig ES, Barnes CA (2003) Impact of aging on hippocampal function: plasticity, network dynamics, and cognition. Prog Neurobiol 69: 143-179.
13. Barnes CA, McNaughton BL (1985) An age comparison of the rates of acquisition and forgetting of spatial information in relation to long-term enhancement of hippocampal synapses. Behav Neurosci 99: 1040-1048.
14. Berger J, Moller DE (2002) The mechanisms of action of PPARs. Annu Rev Med 53: 409-435.
15. Hauner H (2002) The mode of action of thiazolidinediones. Diabetes Metab Res Rev 18 Suppl 2: S10-15.
16. Martin G, Schoonjans K, Lefebvre AM, Staels B, Auwerx J (1997) Coordinate regulation of the expression of the fatty acid transport protein and acyl-CoA synthetase genes by PPARalpha and PPARgamma activators. J Biol Chem 272: 28210-28217.
17. Schoonjans K, Peinado-Onsurbe J, Lefebvre AM, Heyman RA, Briggs M, et al. (1996) PPARalpha and PPARgamma activators direct a distinct tissue-specific transcriptional response via a PPRE in the lipoprotein lipase gene. Embo J 15: 5336-5348.
18. Berger JP, Akiyama TE, Meinke PT (2005) PPARs: therapeutic targets for metabolic disease. Trends Pharmacol Sci 26: 244-251.
19. Hofmann C, Lorenz K, Braithwaite SS, Colca JR, Palazuk BJ, et al. (1994) Altered gene expression for tumor necrosis factor-alpha and its receptors during drug and dietary modulation of insulin resistance. Endocrinology 134: 264-270.
20. Hong C, Tontonoz P (2008) Coordination of inflammation and metabolism by PPAR and LXR nuclear receptors. Curr Opin Genet Dev 18: 461-467.
21. Watson GS, Cholerton BA, Reger MA, Baker LD, Plymate SR, et al. (2005) Preserved cognition in patients with early Alzheimer disease and amnestic mild cognitive impairment during treatment with rosiglitazone: a preliminary study. Am J Geriatr Psychiatry 13: 950-958.
22. Hanyu H, Sato T, Kiuchi A, Sakurai H, Iwamoto T (2009) Pioglitazone improved cognition in a pilot study on patients with Alzheimer's disease and mild cognitive impairment with diabetes mellitus. J Am Geriatr Soc 57: 177-179.
23. Risner ME, Saunders AM, Altman JF, Ormandy GC, Craft S, et al. (2006) Efficacy of rosiglitazone in a genetically defined population with mild-to-moderate Alzheimer's disease. Pharmacogenomics J 6: 246-254.
24. Heneka MT, Sastre M, Dumitrescu-Ozimek L, Hanke A, Dewachter I, et al. (2005) Acute treatment with the PPAR{gamma} agonist pioglitazone and ibuprofen reduces glial inflammation and A{beta}1-42 levels in APPV717I transgenic mice. Brain.
25. Jiang Q, Heneka M, Landreth GE (2008) The role of peroxisome proliferator-activated receptor-gamma (PPARgamma) in Alzheimer's disease: therapeutic implications. CNS Drugs 22: 1-14.
26. Pedersen WA, McMillan PJ, Kulstad JJ, Leverenz JB, Craft S, et al. (2006) Rosiglitazone attenuates learning and memory deficits in Tg2576 Alzheimer mice. Exp Neurol 199: 265-273.
27. Lacombe P, Mathews PM, Schmidt SD, Breidert T, Heneka MT, et al. (2004) Effect of anti-inflammatory agents on transforming growth factor beta over-expressing mouse brains: a model revised. J Neuroinflammation 1: 11.
28. Nicolakakis N, Aboulkassim T, Ongali B, Lecrux C, Fernandes P, et al. (2008) Complete rescue of cerebrovascular function in aged Alzheimer's disease transgenic mice by antioxidants and pioglitazone, a peroxisome proliferator-activated receptor gamma agonist. J Neurosci 28: 9287-9296.
29. Landreth GE, Heneka MT (2001) Anti-inflammatory actions of peroxisome proliferator-activated receptor gamma agonists in Alzheimer's disease. Neurobiol Aging 22: 937-944.
30. Feinstein DL (2003) Therapeutic potential of peroxisome proliferator-activated receptor agonists for neurological disease. Diabetes Technol Ther 5: 67-73.
31. Pancani T, Phelps JT, Searcy JL, Kilgore MW, Chen KC, et al. (2009) Distinct modulation of voltage-gated and ligand-gated Ca2+ currents by PPAR-gamma agonists in cultured hippocampal neurons. J Neurochem 109: 1800-1811.
32. Inestrosa NC, Godoy JA, Quintanilla RA, Koenig CS, Bronfman M (2005) Peroxisome proliferator-activated receptor gamma is expressed in hippocampal neurons and its activation prevents beta-amyloid neurodegeneration: role of Wnt signaling. Exp Cell Res 304: 91-104.
33. Uryu S, Harada J, Hisamoto M, Oda T (2002) Troglitazone inhibits both post-glutamate neurotoxicity and low-potassium-induced apoptosis in cerebellar granule neurons. Brain Res 924: 229-236.
34. Zhao X, Ou Z, Grotta JC, Waxham N, Aronowski J (2006) Peroxisome-proliferator-activated receptor-gamma (PPARgamma) activation protects neurons from NMDA excitotoxicity. Brain Res 1073-1074: 460-469.
35. Goodman DG, Ward JM, Squire RA, Chu KC, Linhart MS (1979) Neoplastic and nonneoplastic lesions in aging F344 rats. Toxicol Appl Pharmacol 48: 237-248.
36. Gillies PS, Dunn CJ (2000) Pioglitazone. Drugs 60: 333-343; discussion 344-335.
37. Brunton LL, Sazo JS, Parker KL (2005) Goodman and Gilman's The pharmacological basis of therapeutics. Eleventh edition. 1860 p.
38. Moyer JR, Jr., Thompson LT, Disterhoft JF (1996) Trace eyeblink conditioning increases CA1 excitability in a transient and learning-specific manner. J Neurosci 16: 5536-5546.
39. Gant JC, Sama MM, Landfield PW, Thibault O (2006) Early and simultaneous emergence of multiple hippocampal biomarkers of aging is mediated by Ca2+-induced Ca2+ release. J Neurosci 26: 3482-3490.
40. Larson J, Wong D, Lynch G (1986) Patterned stimulation at the theta frequency is optimal for the induction of hippocampal long-term potentiation. Brain Res 368: 347-350.
41. deToledo-Morrell L, Geinisman Y, Morrell F (1988) Age-dependent alterations in hippocampal synaptic plasticity: relation to memory disorders. Neurobiol Aging 9: 581-590.
42. Rex CS, Kramar EA, Colgin LL, Lin B, Gall CM, et al. (2005) Long-term potentiation is impaired in middle-aged rats: regional specificity and reversal by adenosine receptor antagonists. J Neurosci 25: 5956-5966.
43. Tombaugh GC, Rowe WB, Chow AR, Michael TH, Rose GM (2002) Theta-frequency synaptic potentiation in CA1 in vitro distinguishes cognitively impaired from unimpaired aged Fischer 344 rats. J Neurosci 22: 9932-9940.
44. Shankar S, Teyler TJ, Robbins N (1998) Aging differentially alters forms of long-term potentiation in rat hippocampal area CA1. J Neurophysiol 79: 334-341.
45. Barnes CA, Rao G, McNaughton BL (1996) Functional integrity of NMDA-dependent LTP induction mechanisms across the lifespan of F-344 rats. Learn Mem 3: 124-137.
46. Deupree DL, Bradley J, Turner DA (1993) Age-related alterations in potentiation in the CA1 region in F344 rats. Neurobiol Aging 14: 249-258.
47. Rowe WB, Blalock EM, Chen KC, Kadish I, Wang D, et al. (2007) Hippocampal expression analyses reveal selective association of immediate-early, neuroenergetic, and myelinogenic pathways with cognitive impairment in aged rats. J Neurosci 27: 3098-3110.
48. Kadish I, Thibault O, Blalock EM, Chen KC, Gant JC, et al. (2009) Hippocampal and cognitive aging across the lifespan: a bioenergetic shift precedes and increased cholesterol trafficking parallels memory impairment. J Neurosci 29: 1805-1816.
49. Blalock EM, Geddes JW, Chen KC, Porter NM, Markesbery WR, et al. (2004) Incipient Alzheimer's disease: microarray correlation analyses reveal major transcriptional and tumor suppressor responses. Proc Natl Acad Sci U S A 101: 2173-2178.
50. Blalock EM, Chen KC, Sharrow K, Herman JP, Porter NM, et al. (2003) Gene microarrays in hippocampal aging: statistical profiling identifies novel processes correlated with cognitive impairment. J Neurosci 23: 3807-3819.
51. Bolstad BM, Collin F, Brettschneider J, Simpson K, Cope L, et al. (2005) Quality Assessment of Affymetrix GeneChip Data. In: Gentleman R, Carey V, Huber W, Irizarry R, Dudoit S, eds. Bioinformatics and Computational Biology Solutions Using R and Bioconductor Springer.
52. Gentleman RC, Carey VJ, Bates DM, Bolstad B, Dettling M, et al. (2004) Bioconductor: open software development for computational biology and bioinformatics. Genome Biol 5: R80.
53. Saeed AI, Sharov V, White J, Li J, Liang W, et al. (2003) TM4: a free, open-source system for microarray data management and analysis. Biotechniques 34: 374-378.
54. Huang da W, Sherman BT, Tan Q, Collins JR, Alvord WG, et al. (2007) The DAVID Gene Functional Classification Tool: a novel biological module-centric algorithm to functionally analyze large gene lists. Genome Biol 8: R183.
55. Benjamini Y, Drai D, Elmer G, Kafkafi N, Golani I (2001) Controlling the false discovery rate in behavior genetics research. Behav Brain Res 125: 279-284.
56. Boyle PJ, King AB, Olansky L, Marchetti A, Lau H, et al. (2002) Effects of pioglitazone and rosiglitazone on blood lipid levels and glycemic control in patients with type 2 diabetes mellitus: a retrospective review of randomly selected medical records. Clin Ther 24: 378-396.
57. Deeg MA, Buse JB, Goldberg RB, Kendall DM, Zagar AJ, et al. (2007) Pioglitazone and rosiglitazone have different effects on serum lipoprotein particle concentrations and sizes in patients with type 2 diabetes and dyslipidemia. Diabetes Care 30: 2458-2464.
58. Goldberg RB, Kendall DM, Deeg MA, Buse JB, Zagar AJ, et al. (2005) A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia. Diabetes Care 28: 1547-1554.
59. Szapary PO, Bloedon LT, Samaha FF, Duffy D, Wolfe ML, et al. (2006) Effects of pioglitazone on lipoproteins, inflammatory markers, and adipokines in nondiabetic patients with metabolic syndrome. Arterioscler Thromb Vasc Biol 26: 182-188.
60. Spanheimer R, Betteridge DJ, Tan MH, Ferrannini E, Charbonnel B (2009) Long-term lipid effects of pioglitazone by baseline anti-hyperglycemia medication therapy and statin use from the PROactive experience (PROactive 14). Am J Cardiol 104: 234-239.
61. Lipscombe LL, Gomes T, Levesque LE, Hux JE, Juurlink DN, et al. (2007) Thiazolidinediones and cardiovascular outcomes in older patients with diabetes. Jama 298: 2634-2643.
62. Gallagher M, Burwell R, Burchinal M (1993) Severity of spatial learning impairment in aging: development of a learning index for performance in the Morris water maze. Behav Neurosci 107: 618-626.
63. Moyer JR, Jr., Thompson LT, Black JP, Disterhoft JF (1992) Nimodipine increases excitability of rabbit CA1 pyramidal neurons in an age-and concentration-dependent manner. J Neurophysiol 68: 2100-2109.
64. Landfield PW, Pitler TA (1984) Prolonged Ca2+-dependent afterhyperpolar-izations in hippocampal neurons of aged rats. Science 226: 1089-1092.
65. Disterhoft JF, Thompson LT, Moyer JR, Jr., Mogul DJ (1996) Calcium-dependent afterhyperpolarization and learning in young and aging hippocam-pus. Life Sci 59: 413-420.
66. Gant JC, Thibault O, (2008) Action potential throughput in aged rat hippocampal neurons: Regulation by selective forms of hyperpolarization. Neurobiol Aging.
67. Foster TC (2007) Calcium homeostasis and modulation of synaptic plasticity in the aged brain. Aging Cell 6: 319-325.
68. Storozhevykh TP, Senilova YE, Persiyantseva NA, Pinelis VG, Pomytkin IA (2007) Mitochondrial respiratory chain is involved in insulin-stimulated hydrogen peroxide production and plays an integral role in insulin receptor autophosphorylation in neurons. BMC Neurosci 8: 84.
69. Lee CK, Weindruch R, Prolla TA (2000) Gene-expression profile of the ageing brain in mice. Nat Genet 25: 294-297.
70. Burger C, Lopez MC, Feller JA, Baker HV, Muzyczka N, et al. (2007) Changes in transcription within the CA1 field of the hippocampus are associated with age-related spatial learning impairments. Neurobiol Learn Mem 87: 21-41.
71. Maeshiba Y, Kiyota Y, Yamashita K, Yoshimura Y, Motohashi M, et al. (1997) Disposition of the new antidiabetic agent pioglitazone in rats, dogs, and monkeys. Arzneimittelforschung 47: 29-35.
72. Arikawa M, Takahashi N, Kira T, Hara M, Yoshimatsu H, et al. (2004) Attenuated inhibition of L-type calcium currents by troglitazone in fructose-fed rat cardiac ventricular myocytes. J Cardiovasc Pharmacol 44: 109-116.
73. Asano M, Nakajima T, Iwasawa K, Morita T, Nakamura F, et al. (1999) Troglitazone and pioglitazone attenuate agonist-dependent Ca2+ mobilization and cell proliferation in vascular smooth muscle cells. Br J Pharmacol 128: 673-683.
74. Heppner TJ, Bonev AD, Eckman DM, Gomez MF, Petkov GV, et al. (2005) Novel PPARgamma agonists GI 262570, GW 7845, GW 1929, and pioglitazone decrease calcium channel function and myogenic tone in rat mesenteric arteries. Pharmacology 73: 15-22.
75. Ikeda S, Watanabe T (1998) Effects of troglitazone and pioglitazone on the action potentials and membrane currents of rabbit ventricular myocytes. Eur J Pharmacol 357: 243-250.
76. Nakajima T, Iwasawa K, Oonuma H, Imuta H, Hazama H, et al. (1999) Troglitazone inhibits voltage-dependent calcium currents in guinea pig cardiac myocytes. Circulation 99: 2942-2950.
77. Song J, Walsh MF, Igwe R, Ram JL, Barazi M, et al. (1997) Troglitazone reduces contraction by inhibition of vascular smooth muscle cell Ca2+ currents and not endothelial nitric oxide production. Diabetes 46: 659-664.
78. Disterhoft JF, Oh MM (2007) Alterations in intrinsic neuronal excitability during normal aging. Aging Cell 6: 327-336.
79. Thibault O, Gant JC, Landfield PW (2007) Expansion of the calcium hypothesis of brain aging and Alzheimer's disease: minding the store. Aging Cell 6: 307-317.
80. Thibault O, Landfield PW (1996) Increase in single L-type calcium channels in hippocampal neurons during aging. Science 272: 1017-1020.
81. Huang TJ, Sayers NM, Fernyhough P, Verkhratsky A (2002) Diabetes-induced alterations in calcium homeostasis in sensory neurones of streptozotocin-diabetic rats are restricted to lumbar ganglia and are prevented by neurotrophin-3. Diabetologia 45: 560-570.
82. Huang TJ, Verkhratsky A, Fernyhough P (2005) Insulin enhances mitochon-drial inner membrane potential and increases ATP levels through phospho-inositide 3-kinase in adult sensory neurons. Mol Cell Neurosci 28: 42-54.
83. Kamal A, Artola A, Biessels GJ, Gispen WH, Ramakers GM (2003) Increased spike broadening and slow afterhyperpolarization in CA1 pyramidal cells of streptozotocin-induced diabetic rats. Neuroscience 118: 577-583.
84. Kruglikov I, Gryshchenko O, Shutov L, Kostyuk E, Kostyuk P, et al. (2004) Diabetes-induced abnormalities in ER calcium mobilization in primary and secondary nociceptive neurons. Pflugers Arch 448: 395-401.
85. Draznin B, Lewis D, Houlder N, Sherman N, Adamo M, et al. (1989) Mechanism of insulin resistance induced by sustained levels of cytosolic free calcium in rat adipocytes. Endocrinology 125: 2341-2349.
86. Escribano L, Simon AM, Perez-Mediavilla A, Salazar-Colocho P, Del Rio J, et al. (2009) Rosiglitazone reverses memory decline and hippocampal glucocorticoid receptor down-regulation in an Alzheimer's disease mouse model. Biochem Biophys Res Commun 379: 406-410.
87. Kerr DS, Campbell LW, Hao SY, Landfield PW (1989) Corticosteroid modulation of hippocampal potentials: increased effect with aging. Science 245: 1505-1509.
88. Bonini JA, Colca JR, Dailey C, White M, Hofmann C (1995) Compensatory alterations for insulin signal transduction and glucose transport in insulin-resistant diabetes. Am J Physiol 269: E759-765.
89. de la Monte SM, Tong M, Lester-Coll N, Plater M, Jr., Wands JR (2006) Therapeutic rescue of neurodegeneration in experimental type 3 diabetes: Relevance to Alzheimer's disease. J Alzheimers Dis 10: 89-109.
90. Steen E, Terry BM, Rivera EJ, Cannon JL, Neely TR, et al. (2005) Impaired insulin and insulin-like growth factor expression and signaling mechanisms in Alzheimer's disease-is this type 3 diabetes? J Alzheimers Dis 7: 63-80.
91. Watson GS, Craft S (2003) The role of insulin resistance in the pathogenesis of Alzheimer's disease: implications for treatment. CNS Drugs 17: 27-45.
92. Barzilai N, Rossetti L (1995) Relationship between changes in body composition and insulin responsiveness in models of the aging rat. Am J Physiol 269: E591-597.
93. Levin BE, Triscari J, Sullivan AC (1983) Relationship between sympathetic activity and diet-induced obesity in two rat strains. Am J Physiol 245: R364-371.
94. Petrova TV, Akama KT, Van Eldik LJ (1999) Cyclopentenone prostaglandins suppress activation of microglia: down-regulation of inducible nitric-oxide synthase by 15-deoxy-Delta12,14-prostaglandin J2. Proc Natl Acad Sci U S A 96: 4668-4673.
95. Combs CK, Johnson DE, Karlo JC, Cannady SB, Landreth GE (2000) Inflammatory mechanisms in Alzheimer's disease: inhibition of beta-amyloid-stimulated proinflammatory responses and neurotoxicity by PPARgamma agonists. J Neurosci 20: 558-567.
96. Heneka MT, Feinstein DL, Galea E, Gleichmann M, Wullner U, et al. (1999) Peroxisome proliferator-activated receptor gamma agonists protect cerebellar granule cells from cytokine-induced apoptotic cell death by inhibition of inducible nitric oxide synthase. J Neuroimmunol 100: 156-168.
97. Jiang C, Ting AT, Seed B (1998) PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines. Nature 391: 82-86.
98. Li M, Pascual G, Glass CK (2000) Peroxisome proliferator-activated receptor gamma-dependent repression of the inducible nitric oxide synthase gene. Mol Cell Biol 20: 4699-4707.
99. Ricote M, Li AC, Willson TM, Kelly CJ, Glass CK (1998) The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation. Nature 391: 79-82.
100. Tureyen K, Kapadia R, Bowen KK, Satriotomo I, Liang J, et al. (2007) Peroxisome proliferator-activated receptor-gamma agonists induce neuropro-tection following transient focal ischemia in normotensive, normoglycemic as well as hypertensive and type-2 diabetic rodents. J Neurochem 101: 41-56.
101. Morgenweck J, Abdel-Aleem OS, McNamara KC, Donahue RR, Badr MZ, et al. (2009) Activation of peroxisome proliferator-activated receptor gamma in brain inhibits inflammatory pain, dorsal horn expression of Fos, and local edema. Neuropharmacology.
102. Churi SB, Abdel-Aleem OS, Tumber KK, Scuderi-Porter H, Taylor BK (2008) Intrathecal rosiglitazone acts at peroxisome proliferator-activated receptor-gamma to rapidly inhibit neuropathic pain in rats. J Pain 9: 639-649.
103. Aoun P, Watson DG, Simpkins JW (2003) Neuroprotective effects of PPARgamma agonists against oxidative insults in HT-22 cells. Eur J Pharmacol 472: 65-71.
104. Garcia-Bueno B, Madrigal JL, Lizasoain I, Moro MA, Lorenzo P, et al. (2005) Peroxisome proliferator-activated receptor gamma activation decreases neuroinflammation in brain after stress in rats. Biol Psychiatry 57: 885-894.
105. Heneka MT, Klockgether T, Feinstein DL (2000) Peroxisome proliferatoractivated receptor-gamma ligands reduce neuronal inducible nitric oxide synthase expression and cell death in vivo. J Neurosci 20: 6862-6867.
106. Hunter RL, Choi DY, Ross SA, Bing G (2008) Protective properties afforded by pioglitazone against intrastriatal LPS in Sprague-Dawley rats. Neurosci Lett 432: 198-201.
107. Romera C, Hurtado O, Mallolas J, Pereira MP, Morales JR, et al. (2007) Ischemic preconditioning reveals that GLT1/EAAT2 glutamate transporter is a novel PPARgamma target gene involved in neuroprotection. J Cereb Blood Flow Metab 27: 1327-1338.
108. Breidert T, Callebert J, Heneka MT, Landreth G, Launay JM, et al. (2002) Protective action of the peroxisome proliferator-activated receptor-gamma agonist pioglitazone in a mouse model of Parkinson's disease. J Neurochem 82: 615-624.
109. Victor NA, Wanderi EW, Gamboa J, Zhao X, Aronowski J, et al. (2006) Altered PPARgamma expression and activation after transient focal ischemia in rats. Eur J Neurosci 24: 1653-1663.
110. Dehmer T, Heneka MT, Sastre M, Dichgans J, Schulz JB (2004) Protection by pioglitazone in the MPTP model of Parkinson's disease correlates with I kappa B alpha induction and block of NF kappa B and iNOS activation. J Neurochem 88: 494-501.
111. Kapadia R, Yi JH, Vemuganti R (2008) Mechanisms of anti-inflammatory and neuroprotective actions of PPAR-gamma agonists. Front Biosci 13: 1813-1826.
112. Sundararajan S, Gamboa JL, Victor NA, Wanderi EW, Lust WD, et al. (2005) Peroxisome proliferator-activated receptor-gamma ligands reduce inflammation and infarction size in transient focal ischemia. Neuroscience 130: 685-696.
113. Pedersen WA, Flynn ER (2004) Insulin resistance contributes to aberrant stress responses in the Tg2576 mouse model of Alzheimer's disease. Neurobiol Dis 17: 500-506.
114. Yan Q, Zhang J, Liu H, Babu-Khan S, Vassar R, et al. (2003) Antiinflammatory drug therapy alters beta-amyloid processing and deposition in an animal model of Alzheimer's disease. J Neurosci 23: 7504-7509.
115. Gemma C, Stellwagen H, Fister M, Coultrap SJ, Mesches MH, et al. (2004) Rosiglitazone improves contextual fear conditioning in aged rats. Neuroreport 15: 2255-2259.
116. Aenlle KK, Kumar A, Cui L, Jackson TC, Foster TC (2009) Estrogen effects on cognition and hippocampal transcription in middle-aged mice. Neurobiol Aging 30: 932-945.
117. Burger C, Lopez MC, Baker HV, Mandel RJ, Muzyczka N (2008) Genomewide analysis of aging and learning-related genes in the hippocampal dentate gyrus. Neurobiol Learn Mem 89: 379-396.
118. Parachikova A, Agadjanyan MG, Cribbs DH, Blurton-Jones M, Perreau V, et al. (2007) Inflammatory changes parallel the early stages of Alzheimer disease. Neurobiol Aging 28: 1821-1833.
119. Stranahan AM, Lee K, Becker KG, Zhang Y, Maudsley S, et al. (2008) Hippocampal gene expression patterns underlying the enhancement of memory by running in aged mice. Neurobiol Aging.
120. Wang X, Zaidi A, Pal R, Garrett AS, Braceras R, et al. (2009) Genomic and biochemical approaches in the discovery of mechanisms for selective neuronal vulnerability to oxidative stress. BMC Neurosci 10: 12.
121. Dasu MR, Park S, Devaraj S, Jialal I (2009) Pioglitazone inhibits Toll-like receptor expression and activity in human monocytes and db/db mice. Endocrinology 150: 3457-3464.